Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.

about

Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.

Item

http://www.wikidata.org/entity/Q48097743

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Plerixafor in poor mobilizers ...... i-center time-motion analysis.

@en

Plerixafor in poor mobilizers ...... i-center time-motion analysis.

@nl

type

Item

label

Plerixafor in poor mobilizers ...... i-center time-motion analysis.

@en

Plerixafor in poor mobilizers ...... i-center time-motion analysis.

@nl

prefLabel

Plerixafor in poor mobilizers ...... i-center time-motion analysis.

@en

Plerixafor in poor mobilizers ...... i-center time-motion analysis.

@nl

P1476

Plerixafor in poor mobilizers ...... i-center time-motion analysis.

@en

P2093

Anna Kron

http://www.w3.org/2001/XMLSchema#string

Bertram Glaß

http://www.w3.org/2001/XMLSchema#string

Florian Kron

http://www.w3.org/2001/XMLSchema#string

Gary Milkovich

http://www.w3.org/2001/XMLSchema#string

Helmut Ostermann

http://www.w3.org/2001/XMLSchema#string

Kai Hübel

http://www.w3.org/2001/XMLSchema#string

Lionel Karlin

http://www.w3.org/2001/XMLSchema#string

Lucia Farina

http://www.w3.org/2001/XMLSchema#string

Mohamad Mohty

http://www.w3.org/2001/XMLSchema#string

Nabih Azar

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.

Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma.

P2888

s41409-017-0033-0

P304

246-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41409-017-0033-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christian Chabannon

P577

2017-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29255168

http://www.w3.org/2001/XMLSchema#string